NSE · 3BBLACKBIO
3B BlackBio DX Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹25 Cr with net profit ₹7 Cr — a 30.25% net margin, versus 59.31% the period before.
Shareholding
As of 2026-06-30
- Promoter40.95%
- Public54.4%
- FII2.5%
- DII2.15%
11,049 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.33× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #29 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,572 Cr | 242.86 | 13.56 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,001 Cr | 315.26 | 10.05 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,868 Cr | 270.44 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,509 Cr | 188.76 | 9.37 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,385 Cr | 300.75 | 9.26 | 8.48% | 8.36% |
| Global Health Limited | ₹38,058 Cr | 264.09 | 9.6 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,737 Cr | 748.25 | 14.12 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,501 Cr | 239.07 | 12.56 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹16,996 Cr | 256.4 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,545 Cr | 392.32 | 7.67 | 6.58% | 6.4% |
| 3B BlackBio DX Ltd.(this company) | ₹1,097 Cr | 111.7 | 3.38 | 18.06% | 41.29% |
AI analysis
AI-generated · google/gemini-2.5-flash3B BlackBio DX Ltd. has a market capitalization of Rs 1088 Cr. The company reported a revenue of Rs 111.55 Cr and a profit margin of 41.29%. Earnings per share (EPS) for the last reported period was Rs 68.26. The stock's 52-week high is Rs 1441.5 and its 52-week low is Rs 1085.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +The profit margin is 41.29%, suggesting efficient operations.
- +Return on capital employed (ROCE) is 23.58%, indicating effective use of capital.
Negatives
- −The promoter holding decreased from an unspecified value to 40.95% as of June 30, 2026.
- −Quarterly revenue saw a decline from Rs 50.35 Cr in December 2025 to Rs 35.43 Cr in March 2026.
- −Quarterly net profit decreased from Rs 21.73 Cr in December 2025 to Rs 9.56 Cr in March 2026.
Financial performance
The company's revenue for the fiscal year ending March 2025 was Rs 111.55 Cr, with a net profit of Rs 47.69 Cr. In the quarter ending March 2026, revenue was Rs 35.43 Cr and net profit was Rs 9.56 Cr. For the December 2025 quarter, revenue was Rs 50.35 Cr and net profit was Rs 21.73 Cr.
Profitability & returns
3B BlackBio DX Ltd. achieved a profit margin of 41.29%. The return on equity (ROE) was 18.06% and the return on capital employed (ROCE) was 23.58%. Earnings per share (EPS) for the last reported period stands at Rs 68.26.
Balance sheet
The company has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 377.96. No pledge information for promoter holdings has been reported.
Ownership & pledges
As of June 30, 2026, promoters held 40.95% of the shares, while public shareholders held 54.40%. FIIs held 2.50% and DIIs held 2.15%. Total institutional holding was 4.65%. The number of shareholders was 11049. There were no promoter pledges reported.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.